Mar 28 |
Top 5 Health Care Stocks That May Plunge In March
|
Mar 26 |
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
|
Mar 12 |
Inozyme Pharma: Q4 Earnings Insights
|
Mar 12 |
Inozyme Pharma GAAP EPS of -$1.37
|
Mar 12 |
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
|
Mar 8 |
Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward
|
Feb 26 |
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
|
Dec 21 |
Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)
|
Nov 27 |
Inozyme: A Major Catalyst Is Uncomfortably Far Off
|
Nov 9 |
Inozyme Pharma to Participate in Upcoming Investor Conferences
|